These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Oral oxymorphone (Opana). Med Lett Drugs Ther; 2007 Jan; 49(1251):3-4. PubMed ID: 17179898 [No Abstract] [Full Text] [Related]
23. Successful treatment of intravenously abused oral Opana ER-induced thrombotic microangiopathy without plasma exchange. Miller PJ; Farland AM; Knovich MA; Batt KM; Owen J Am J Hematol; 2014 Jul; 89(7):695-7. PubMed ID: 24668845 [TBL] [Abstract][Full Text] [Related]
24. The Frequency and Outcome of Acute Kidney Injury in a Tertiary Hospital: Which Factors Affect Mortality? Ulusoy S; Arı D; Ozkan G; Cansız M; Kaynar K Artif Organs; 2015 Jul; 39(7):597-606. PubMed ID: 25865634 [TBL] [Abstract][Full Text] [Related]
25. A comparison of the systems for the identification of postoperative acute kidney injury in pediatric cardiac patients. Lex DJ; Tóth R; Cserép Z; Alexander SI; Breuer T; Sápi E; Szatmári A; Székely E; Gál J; Székely A Ann Thorac Surg; 2014 Jan; 97(1):202-10. PubMed ID: 24206964 [TBL] [Abstract][Full Text] [Related]
26. Acute Sensorineural Hearing Loss After Abuse of an Inhaled, Crushed Oxymorphone Extended-Release Tablet. MacDonald LE; Onsrud JE; Mullins-Hodgin R Pharmacotherapy; 2015 Jul; 35(7):e118-21. PubMed ID: 26112082 [TBL] [Abstract][Full Text] [Related]
27. AKI in hospitalized children: comparing the pRIFLE, AKIN, and KDIGO definitions. Sutherland SM; Byrnes JJ; Kothari M; Longhurst CA; Dutta S; Garcia P; Goldstein SL Clin J Am Soc Nephrol; 2015 Apr; 10(4):554-61. PubMed ID: 25649155 [TBL] [Abstract][Full Text] [Related]
28. Evolution of chronic renal impairment and long-term mortality after de novo acute kidney injury in the critically ill; a Swedish multi-centre cohort study. Rimes-Stigare C; Frumento P; Bottai M; Mårtensson J; Martling CR; Walther SM; Karlström G; Bell M Crit Care; 2015 May; 19(1):221. PubMed ID: 25944032 [TBL] [Abstract][Full Text] [Related]
29. Clinical applications of oxymorphone. Vadivelu N; Maria M; Jolly S; Rosenbloom J; Prasad A; Kaye AD J Opioid Manag; 2013; 9(6):439-52. PubMed ID: 24481932 [TBL] [Abstract][Full Text] [Related]
30. Opana ER (Oxymorphone)-Induced Thrombotic Microangiopathy: An Atypical Presentation in a Patient With Hepatitis C. Mehmood H; Khan M; Marwat A; Joshi M; Malhotra V J Investig Med High Impact Case Rep; 2018; 6():2324709618756423. PubMed ID: 29435466 [TBL] [Abstract][Full Text] [Related]
31. Efficacy and safety of OPANA ER (oxymorphone extended release) for relief of moderate to severe chronic low back pain in opioid-experienced patients: a 12-week, randomized, double-blind, placebo-controlled study. Hale ME; Ahdieh H; Ma T; Rauck R; J Pain; 2007 Feb; 8(2):175-84. PubMed ID: 17145204 [TBL] [Abstract][Full Text] [Related]
32. Long-Term Mortality among Hospitalized Non-ICU Patients with Acute Kidney Injury Referred to Nephrology. Ruiz-Criado J; Ramos-Barron MA; Fernandez-Fresnedo G; Rodrigo E; De Francisco AL; Arias M; Gomez-Alamillo C Nephron; 2015; 131(1):23-33. PubMed ID: 26277844 [TBL] [Abstract][Full Text] [Related]
33. Bioequivalence of oxymorphone extended release and crush-resistant oxymorphone extended release. Benedek IH; Jobes J; Xiang Q; Fiske WD Drug Des Devel Ther; 2011; 5():455-63. PubMed ID: 22162639 [TBL] [Abstract][Full Text] [Related]
34. Risk factors, mortality and acute kidney injury outcomes in cirrhotic patients in the emergency department. Gessolo Lins PR; Carvalho Padilha WS; Magalhaes Giradin Pimentel CF; Costa Batista M; Teixeira de Gois AF BMC Nephrol; 2018 Oct; 19(1):277. PubMed ID: 30342475 [TBL] [Abstract][Full Text] [Related]
35. Feasibility study of rapid opioid rotation and titration. Korkmazsky M; Ghandehari J; Sanchez A; Lin HM; Pappagallo M Pain Physician; 2011; 14(1):71-82. PubMed ID: 21267044 [TBL] [Abstract][Full Text] [Related]
36. Cumulative fluid accumulation is associated with the development of acute kidney injury and non-recovery of renal function: a retrospective analysis. Zhang J; Crichton S; Dixon A; Seylanova N; Peng ZY; Ostermann M Crit Care; 2019 Dec; 23(1):392. PubMed ID: 31796077 [TBL] [Abstract][Full Text] [Related]
37. Oxymorphone extended-release tablets relieve moderate to severe pain and improve physical function in osteoarthritis: results of a randomized, double-blind, placebo- and active-controlled phase III trial. Matsumoto AK; Babul N; Ahdieh H Pain Med; 2005; 6(5):357-66. PubMed ID: 16266356 [TBL] [Abstract][Full Text] [Related]
38. Incidence and outcome of contrast-associated acute kidney injury assessed with Risk, Injury, Failure, Loss, and End-stage kidney disease (RIFLE) criteria in critically ill patients of medical and surgical intensive care units: a retrospective study. Kim MH; Koh SO; Kim EJ; Cho JS; Na SW BMC Anesthesiol; 2015; 15():23. PubMed ID: 25780349 [TBL] [Abstract][Full Text] [Related]
39. International statistical classification of diseases and related health problems coding underestimates the incidence and prevalence of acute kidney injury and chronic kidney disease in general medical patients. Ko S; Venkatesan S; Nand K; Levidiotis V; Nelson C; Janus E Intern Med J; 2018 Mar; 48(3):310-315. PubMed ID: 29283473 [TBL] [Abstract][Full Text] [Related]